RGBP · Regen BioPharma Inc
$0.00
+0.00 (+0.00%)
At close · Sep 1
Going-concern doubt
— flagged Aug 17, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Without additional funding, there is substantial doubt about the Company's ability to continue as a going concern for the twelve months from the date of these financial statements.”View the 10-Q filed Aug 17, 2026
Market Cap
$167,527
Shares
1.68B
RGBP metrics
48 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.00
Market cap
$167,527
Price action
19 metricsPrice change (1W)
+0.0%
Price change (30D)
-50.0%
Price change (3M)
-50.0%
Price change (6M)
-90.9%
Price change (YTD)
-98.6%
Price change (1Y)
-99.5%
Trailing year
Price change (5Y)
—
52-week high
$0.03
52-week low
$0.00
Change from 52-week high
-99.6%
Change from 52-week low
+0.0%
Annualized volatility
453.4%
Beta
4.4
RSI (14D)
46.5
Price vs SMA 50
-29.6%
Price vs SMA 200
-96.5%
Avg volume (3M)
24.18M
Relative volume
0.6
Average dollar volume
$3,261
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
1.68B
Valuation
12 metricsP / E (TTM)
0.0
Trailing earnings · reciprocal yield 80,000.0%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.7×
reciprocal yield 141.2%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-708.1%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
-339.8%
Trailing 12 months
Net margin
-501.4%
Gross profit (TTM)
—
Operating profit (TTM)
−$803,862
Net income (TTM)
−$1.19M
Trailing 12 months
Diluted EPS (TTM)
$0.08
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+0.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$236,561
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2,491.5%
Year over year · more shares
Revenue CAGR (3Y)
+23.5%
Revenue CAGR (5Y)
+16.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-412.5%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
-4.7
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$239
Total assets
$287,587
Total debt
$107,057
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$445,249
Capital expenditures (TTM)
—
R&D (TTM)
$223,941
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
94.7%
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Short interest
3 metricsShort interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged